# US 2021/0275549 A1 · Novel formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275549 A1
- Document ID: US20210275549A1
- Status: Published application
- Kind: A1
- Application number: 17/099,435
- Filed: 2020-11-16
- Published: 2021-09-09
- Earliest claimed: 2013-11-06
- Assignees: Aeromics, Inc.
- Applicants: Aeromics, Inc.
- Inventors: Marc F. PELLETIER; Paul Robert MCGUIRK; George William FARR
- Web page: https://patentgrep.com/patent/US20210275549A1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 9/09: Esters of phosphoric acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.

## Claims

### Claim at position 1

1-87. (canceled)

### Claim 88

A pharmaceutical composition comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate (Formula I)
and one or more Bronsted bases, wherein the one or more Bronsted bases are an amine and/or a salt thereof, and the pharmaceutical composition comprises <2% N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide after one week at room temperature.

### Claim 89 (depends on 88)

The pharmaceutical composition of claim 88, wherein the pharmaceutical composition is suitable for dissolution with an aqueous solution to form an injection.

### Claim 90 (depends on 89)

The pharmaceutical composition of claim 89, wherein upon dissolution of the pharmaceutical composition in the aqueous solution the pharmaceutical composition has a pH between 7 and 9.5.

### Claim 91 (depends on 89)

The pharmaceutical composition of claim 89, wherein upon dissolution of the pharmaceutical composition in the aqueous solution the pharmaceutical composition has a pH between 8 and 9.5.

### Claim 92 (depends on 89)

The pharmaceutical composition of claim 89, wherein upon dissolution of the pharmaceutical composition in the aqueous solution the pharmaceutical composition has a pH between 8 and 8.5.

### Claim 93 (depends on 88)

The pharmaceutical composition of claim 88, wherein the pharmaceutical composition comprises <1% N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide after one week at room temperature.

### Claim 94 (depends on 88)

The pharmaceutical composition of claim 88, wherein a conjugate acid of the one or more Bronsted bases has a pKa between 6 and 11.

### Claim 95 (depends on 88)

The pharmaceutical composition of claim 88, wherein a conjugate acid of the one or more Bronsted bases has a pKa between 8 and 10.

### Claim 96 (depends on 88)

The pharmaceutical composition of claim 88, wherein the one or more Bronsted bases are one or more of H2NR20, HNR20R21, NR20R21R22, and/or a salt thereof, wherein each R20, R21, and R22 are independently C1-8 alkyl optionally substituted with one or more —OH.

### Claim 97 (depends on 88)

The pharmaceutical composition of claim 88, wherein the one or more Bronsted bases are tris(hydroxymethyl)aminomethane, meglumine, and/or a tris(hydroxymethyl)aminomethane salt.

### Claim 98 (depends on 88)

The pharmaceutical composition of claim 88, wherein the molar ratio of Formula I to the one or more Bronsted bases is at least 1:2.

### Claim 99 (depends on 89)

The pharmaceutical composition of claim 89, wherein the aqueous solution is sterile water for injection, a sterile solution comprising dextrose, a sterile solution comprising sodium chloride, a sterile solution comprising benzyl alcohol, or Lactated Ringer's.

### Claim 100 (depends on 89)

The pharmaceutical composition of claim 89, wherein the aqueous solution is sterile water for injection or 0.9% sodium chloride injection.

### Claim 101 (depends on 89)

The pharmaceutical composition of claim 89, wherein the pharmaceutical composition is for injection intravenously.

### Claim 102 (depends on 88)

A method of making the pharmaceutical composition of claim 88, wherein the method comprises admixing Formula I and an amine and/or a salt thereof.
